Befotertinib plus chemo for EGFR-mutated lung cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug, befotertinib, combined with chemotherapy as a first treatment for advanced lung cancer with an EGFR mutation. It aims to see if this approach can improve outcomes and uses a special blood test to guide treatment adjustments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced non-small cell lung cancer (stage IIIB or IV) with an EGFR mutation (exon 19 deletion or L858R).
- You have not received any prior cancer treatment for this condition.
- You are at least 18 years old and able to take oral medication.
- Your overall health is fairly good (ECOG score 0-2, meaning you can care for yourself or are up and about at least half the day).
- Your blood counts and organ function are within acceptable ranges (kidney, liver, and blood cells).
- You agree to use effective birth control if you are fertile, and are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of pembrolizumab (an immunotherapy) and chemotherapy for people with advanced non-squamous non-small cell lung cancer that has a specific EGFR mutation (exon 21) and a PD-L1 score of 1% or higher. It aims to see if this combination can help shrink tumors and improve outcomes for those who have not yet received any anticancer treatment.
This trial tests a combination of chemotherapy and a targeted drug (befotertinib) for people with non-small cell lung cancer whose cancer has stopped responding to a common type of targeted therapy. It aims to see if this new sequence can help overcome resistance.
This trial tests a new drug called BEBT-109 for people with a specific type of non-small cell lung cancer that has an EGFR exon 20 insertion mutation. It's for those who haven't had prior treatment for advanced or metastatic lung cancer, and it aims to see if the drug can help shrink or control the cancer.
This study tests two oral targeted drugs, Befotertinib and Icotinib, in people with advanced lung cancer (NSCLC) that has one of three uncommon EGFR mutations. The trial aims to see how well these pills work when used as the first treatment for your cancer.
This trial tests a targeted therapy (Befotertinib) combined with radiation for people with a specific EGFR mutation whose lung cancer has spread to a few spots. It aims to see if ctDNA monitoring can guide treatment.
This trial tests a drug called Befotertinib for people with non-small cell lung cancer that has uncommon EGFR mutations (like G719X, L861Q, S768I, or exon 20 insertions). It is for those who haven't taken an EGFR-targeted pill before and have had a previous chemotherapy stopped working or caused side effects.
Hear when a new EGFR Exon 21 Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.